A Study of Pharmacogenomics Testing in Patients Who Experience Bleeding While on Apixaban or Warfarin

Overview

About this study

The purpose of htis study is to see if PGx testing will help to determine better ways for doctors to use apixaban treatment.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Subjects must be > 18 years of age who are on ongoing treatment with apixaban with one or more of the following criteria will be included:

  • A condition that would require long term anticoagulation with one of the DOAC such as recurrent venous thromboembolic disease or atrial fibrillation plus one of the points below.
    • Recent GI bleeding while on apixaban therapy.
    • Prior history of bleeding with warfarin.

  Exclusion Criteria:

  • Pregnant patients
  • Renal impairment (GFR less than 50 mg/dl)
  • Contraindication for apixaban use
  • Mentally incapable of signing a consent form
  • Patients with history of valvular heart disease
  • Patients with known anti-phospholipid syndrome
  • Patients with active malignancy

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Fadi Shamoun, M.D.

Closed for enrollment

Rochester, Minn.

Mayo Clinic principal investigator

Fadi Shamoun, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20425268

Mayo Clinic Footer